DAXOCOX® – WEEKLY OA PAIN RELIEF
THE FIRST AND ONLY NSAID
DAXOCOX® HELPS RELIEVE OA PAIN
OWNER COMPLIANCE
Simple weekly dosing with a flavoured tablet
7x less risk of a missed dose, compared to daily dosing
CONSISTENT PLASMA LEVELS
Consistent Pain Control for 7 days
Daxocox® reaches minimum effective concentration within 24 hours after the 1st “loading dose” and stays at the required therapeutic level for 7 days until the next dose is due5,6
FLARE UPS
Reliable analgesia
The combination of proven 7-day efficacy with easy weekly dosing of Daxocox® helps to minimise the clinical consequences of unavoidable OA flare-ups
DISEASE PROGRESSION
Licensed for all stages of OA
Can be given continuously, with no mandatory treatment breaks, making Daxocox® a suitable NSAID cornerstone of a responsive multi-modal management approach
EFFECTIVE MANAGEMENT OF OA PAIN
Once weekly dosing with Daxocox® achieves significant improvement of clinical signs associated with OA pain7,8
- Owners report that 90% of dogs with OA improve after treatment with Daxocox®6>
- Owners also report that 84% of dogs improved their quality of life from “poor or fair” to “good, very good or excellent”7
- According to veterinary assessment 74% of dogs showed significant improvement of clinical signs of osteoarthritis7
Clinical study design:
Multicentre, randomised, single blinded clinical field trials (x2) to assess the efficacy of Daxocox®
The study inclusion criteria included:
- > 12 months
- > 5kg body weight
- Clinical signs of osteoarthritis for > 3 weeks
- Confirmed radio graphic evidence of osteoarthritis
- Minimum clinical sum scores (CSS)
- Basal haematology and biochemistry within normal limits
- Received no OA treatment or nutraceutical for an appropriate period of time prior to the study
Both veterinary and owner assessment of improvement was included:
- The following clinical signs were assessed by vets separately, to generate a clinical sum score (CSS) at each examination:
- Posture, stance and weight bearing
- Lameness at walk
- Lameness at trot
- Pain on palpation and manipulation
- Owners completed a subjective assessment, via a questionnaire with a series of set ‘ranking questions’, to generate comparable Canine Brief Pain inventory Scores and QoL analysis
- Investigated perceived pain levels over varying time periods and during different daily activities
DAXOCOX® IS WELL TOLERATED
Daxocox® has a broad margin of safety:
- Clinical field trials noted that, as with all NSAIDs, adverse effects are mostly related to the gastrointestinal system and most cases recovered without treatment13
- The target animal safety study demonstrates that administering up to 5x the recommended therapeutic dose did not show any relevant treatment related adverse effects8
- Suitable for long-term use, with no evidence of drug over-accumulation and no need for therapeutic breaks13
Elevated blood urea and serum cholesterol levels were observed in some cases, at both the recommended dose and overdose.
In case of adverse reactions, the use of the veterinary medicinal product should be stopped and general supportive therapy, as for clinical overdose with NSAIDs, should be applied until complete resolution of the signs.
